From GlobeNewswire:

In 2024, Annexon, Inc. will be reaching significant milestones in the development of potential treatments for various diseases. ANX005 for Guillain-Barré Syndrome (GBS) is on track to report pivotal data from its Phase 3 trial in the first half of 2024, potentially becoming the first approved treatment for GBS patients in the U.S. The company is also set to initiate a global pivotal program for ANX007 in Geographic Atrophy (GA) and advance ANX1502, an oral small molecule inhibitor, into a proof-of-concept trial for autoimmune diseases. Annexon will present a pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference.



Read more: Annexon Outlines 2024 Priorities with Late-Stage Clinical